Literature DB >> 10084817

Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients.

M Boeckh, R A Bowden, T Gooley, D Myerson, L Corey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10084817

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  30 in total

1.  Real-time PCR assay compared to nested PCR and antigenemia assays for detecting cytomegalovirus reactivation in adult T-cell leukemia-lymphoma patients.

Authors:  Junji Ikewaki; Eiichi Ohtsuka; Rie Kawano; Masao Ogata; Hiroshi Kikuchi; Masaru Nasu
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

Review 2.  Specific infectious complications after stem cell transplantation.

Authors:  Holger Hebart; Hermann Einsele
Journal:  Support Care Cancer       Date:  2003-08-15       Impact factor: 3.603

3.  Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.

Authors:  Margaret L Green; Wendy Leisenring; Daniel Stachel; Steven A Pergam; Brenda M Sandmaier; Anna Wald; Lawrence Corey; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-07       Impact factor: 5.742

4.  HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation.

Authors:  Danielle M Zerr; Michael Boeckh; Colleen Delaney; Paul J Martin; Hu Xie; Amanda L Adler; Meei-Li Huang; Lawrence Corey; Wendy M Leisenring
Journal:  Biol Blood Marrow Transplant       Date:  2012-05-26       Impact factor: 5.742

5.  Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report.

Authors:  M D Aljurf; S Z Zaidi; H El Solh; F Hussain; A Ghavamzadeh; H K Mahmoud; T Shamsi; T Ben Othman; M M Sarhan; D Dennison; A Ibrahim; S Benchekroun; N Chaudhri; B Labar; M Horowitz; D Niederwieser; A Gratwohl
Journal:  Bone Marrow Transplant       Date:  2008-12-01       Impact factor: 5.483

6.  Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea.

Authors:  Su-Mi Choi; Dong-Gun Lee; Jung-Hyun Choi; Jin-Hong Yoo; Yoo-Jin Kim; Sun Hee Park; Sun-Nam Park; Chang-Ki Min; Seok Lee; Hee-Je Kim; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Wan-Shik Shin; Chun-Choo Kim
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

7.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

8.  Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients.

Authors:  Lynn El Haddad; Shashank S Ghantoji; Anne K Park; Marjorie V Batista; Jonathan Schelfhout; Jack Hachem; Yadira Lobo; Ying Jiang; Gabriela Rondon; Richard Champlin; Roy F Chemaly
Journal:  J Med Virol       Date:  2019-09-03       Impact factor: 2.327

9.  Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma.

Authors:  Marianne Leruez-Ville; Marie Ouachée; Richard Delarue; Anne-Sophie Sauget; Stéphane Blanche; Agnès Buzyn; Christine Rouzioux
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

Review 10.  Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants.

Authors:  Ellen Meijer; Greet J Boland; Leo F Verdonck
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.